NsGene's protein Neublastin advances into development phase  

The Danish biotech company has announced that Biogen Idec has moved Neublastin from research into development for treatment of neuropathic pain

The Danish biotech company NsGene has announced that Biogen Idec has moved Neublastin, NsGene's proprietary protein, from research into development for treatment of neuropathic pain. NSGene entered a collaboration and licence agreement with Biogen Idec in 2000 which means that Biogen Idec holds the exclusive rights to use Neublastin for indications outside the central nervous system.


Michael Gilman, executive vice president at Biogen Idec says that its research on Neublastin indicates that the molecule is a promising and novel therapeutic approach for managing neuropathic pain and that the company looks forward to assessing its potential utility in clinical trials in the near future.


Under the terms of the agreement, NSGene will receive fees and milestone payments in addition to royalties if a product is successfully developed and commercialised by Biogen Idec. The total sum could amount to DKK 117 mn (USD 20 mn).


NsGene was founded in 1999 as a spin-off from biopharmaceutical company NeuroSearch. It employs 24 people and is located in Ballerup near Copenhagen in the Medicon Valley Region. The news is reported in a press release from NsGene and by business newspaper Erhvervsbladet.


Link > NsGene 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×